These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

492 related items for PubMed ID: 20074016

  • 21. Pathways and targets in hepatocellular carcinoma.
    Psyrri A, Arkadopoulos N, Vassilakopoulou M, Smyrniotis V, Dimitriadis G.
    Expert Rev Anticancer Ther; 2012 Oct; 12(10):1347-57. PubMed ID: 23176622
    [Abstract] [Full Text] [Related]

  • 22. Emerging targeted strategies in advanced hepatocellular carcinoma.
    Finn RS.
    Semin Liver Dis; 2013 Feb; 33 Suppl 1():S11-9. PubMed ID: 23457035
    [Abstract] [Full Text] [Related]

  • 23. Targeting tyrosine kinase receptors in hepatocellular carcinoma.
    Muntané J, De la Rosa AJ, Docobo F, García-Carbonero R, Padillo FJ.
    Curr Cancer Drug Targets; 2013 Mar; 13(3):300-12. PubMed ID: 23016985
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Successful targeted therapies for hepatocellular carcinoma: are we really getting there?
    Zhu AX.
    Expert Rev Anticancer Ther; 2008 Apr; 8(4):499-505. PubMed ID: 18402516
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
    Yau T, Pang R, Chan P, Poon RT.
    Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
    [Abstract] [Full Text] [Related]

  • 28. Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.
    Zhou Q, Lui VW, Yeo W.
    Future Oncol; 2011 Oct; 7(10):1149-67. PubMed ID: 21992728
    [Abstract] [Full Text] [Related]

  • 29. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C.
    Cancer Res; 2006 Dec 15; 66(24):11851-8. PubMed ID: 17178882
    [Abstract] [Full Text] [Related]

  • 30. Targeted therapies for hepatocellular carcinoma.
    Skelton MR, O'Neil B.
    Clin Adv Hematol Oncol; 2008 Mar 15; 6(3):209-18. PubMed ID: 18391920
    [Abstract] [Full Text] [Related]

  • 31. AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma.
    Huynh H.
    Cancer; 2010 Mar 01; 116(5):1315-25. PubMed ID: 20101735
    [Abstract] [Full Text] [Related]

  • 32. New drugs for the treatment of hepatocellular carcinoma.
    Boucher E, Forner A, Reig M, Bruix J.
    Liver Int; 2009 Jan 01; 29 Suppl 1():148-58. PubMed ID: 19207980
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Opportunities and obstacles to combination targeted therapy in renal cell cancer.
    Sosman JA, Puzanov I, Atkins MB.
    Clin Cancer Res; 2007 Jan 15; 13(2 Pt 2):764s-769s. PubMed ID: 17255307
    [Abstract] [Full Text] [Related]

  • 35. Targeted therapy of hepatocellular carcinoma: present and future.
    Chan SL, Yeo W.
    J Gastroenterol Hepatol; 2012 May 15; 27(5):862-72. PubMed ID: 22369685
    [Abstract] [Full Text] [Related]

  • 36. Signaling pathways in hepatocellular carcinoma.
    Sia D, Villanueva A.
    Oncology; 2011 May 15; 81 Suppl 1():18-23. PubMed ID: 22212931
    [Abstract] [Full Text] [Related]

  • 37. Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma.
    Pang R, Poon RT.
    Cancer Lett; 2006 Oct 28; 242(2):151-67. PubMed ID: 16564617
    [Abstract] [Full Text] [Related]

  • 38. Key cancer cell signal transduction pathways as therapeutic targets.
    Bianco R, Melisi D, Ciardiello F, Tortora G.
    Eur J Cancer; 2006 Feb 28; 42(3):290-4. PubMed ID: 16376541
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.
    Schulze-Bergkamen H, Fleischer B, Schuchmann M, Weber A, Weinmann A, Krammer PH, Galle PR.
    BMC Cancer; 2006 Oct 02; 6():232. PubMed ID: 17014711
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 25.